Group Lung Bacteria – Key Publications (2013-current)
1. Kidd TJ, Ramsay KA, Hu H, et al. Shared Pseudomonas aeruginosa genotypes are common in
Australian cystic fibrosis centres. The European respiratory journal 2013; 41(5): 1091-100.
2. Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with
cystic fibrosis. The Lancet Respiratory medicine 2013; 1(2): 164-74.
3. Ramsay KA, Butler CA, Paynter S, Ware R, Kidd TJ, Wainwright CE, Bell SC. Factors influencing
acquisition of Burkholderia cepacia complex in patients with cystic fibrosis. J Clin Micro
2013; 51(12): 3975-80.
4. Price EP, Sarovich DS, Mayo M, Tuanyok A, Drees KP, Kaestli M, Beckstrom-Sternberg SM,
Beckstrom-Sternberg J, Kidd TJ, Bell SC, Keim P, Pearson T, Currie BJ. In vivo evolution of
Burkholderia pseudomallei over a twelve-year chronic carriage infection. mBio 2013; 4(4):
e00388-13.
5. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator
(ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR
mutation: a phase 2 randomised controlled trial. The Lancet Respiratory medicine 2014; 2(7):
527-38.
6. Knibbs LD, Johnson GR, Kidd TJ, et al. Viability of Pseudomonas aeruginosa in cough aerosols
generated by persons with cystic fibrosis. Thorax 2014; 69(8): 740-5.
7. Smith C, Gras S, Brennan RM, et al. Molecular imprint of exposure to naturally occurring
genetic variants of human cytomegalovirus on the T cell repertoire. Scientific reports 2014;
4: 3993.
8. Smith DJ, Badrick AC, Zakrzewski M, et al. Pyrosequencing reveals transient cystic fibrosis
lung microbiome changes with intravenous antibiotics. The European respiratory journal
2014; 44(4): 922-30.
9. Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of
people with cystic fibrosis. Lancet 2014;384(9944):703-13.
10. Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC,
Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM. Mechanisms of reduced
susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from
cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 2014; 69(10):2690-8.
11. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis:
promises, progress, pitfalls. Pharmacology & therapeutics 2015; 145: 19-34.
12. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in
children and adults in Australia and New Zealand Thoracic Society of Australia and New
Zealand guidelines. The Medical journal of Australia 2015; 202(3): 130.
13. Elborn JS, Bell SC, Madge SL, et al. Report of the ERS /ECFS Task force on the care of adults
with cystic fibrosis. european Respiratory Journal 2015: in press.
14. Elborn JS, Geller DE, Conrad D, et al. A phase 3, open-label, randomized trial to evaluate the
safety and efficacy of Levofloxacin Inhalation Solution (APT-1026) versus Tobramycin
Inhalation Solution in stable cystic fibrosis patients. J Cystic Fibrosis 2015; 14(4): 507-14.
15. Kidd TJ, Ramsay KA, Vidmar S, et al. Pseudomonas aeruginosa genotypes acquired by
children with cystic fibrosis by age 5-years. Journal of cystic fibrosis : official journal of the
European Cystic Fibrosis Society 2015; 14(3): 361-9.
16. Kidd TJ, Soares Magalhães RJ, Paynter S, Bell SC, Group. TAI. The social network of cystic
fibrosis centre care and shared Pseudomonas aeruginosa infection: a cross-sectional
analysis. Lancet Respiratory Medicine 2015: in press.
17. Ratjen F, Bell SC, Rowe S, Goss CH, Quittner AL, Bush A. Cystic Fibrosis. Nat Rev Dis Primers
2015: 15010.
18. Smet B, Mayo M, Peeters C, et al. Burkholderia stagnalis sp. nov. and Burkholderia territorii
sp. nov., two novel Burkholderia cepacia complex species from environmental and human
sources. International journal of systematic and evolutionary microbiology 2015.
19. Viberg LT, Price EP, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. Whole-Genome Sequences of Five
Burkholderia pseudomallei Isolates from Australian Cystic Fibrosis Patients. Genome
announcements 2015; 3(2).